Escherichia coli lipopolysaccharide may affect the endothelial barrier and IL-10 expression of apolipoprotein B100-pulsed dendritic cells.
Apolipoprotein B-100
/ pharmacology
Cells, Cultured
Coculture Techniques
Dendritic Cells
/ drug effects
Escherichia coli
/ chemistry
Human Umbilical Vein Endothelial Cells
/ drug effects
Humans
Interleukin-10
/ genetics
Ketocholesterols
/ pharmacology
Lipopolysaccharides
/ immunology
Occludin
/ genetics
Signal Transduction
/ drug effects
Tight Junction Proteins
/ genetics
Tight Junctions
/ drug effects
Apolipoprotein B100
E. coli lipopolysaccharide
barrier functions
endothelium
tight junctions
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
07
03
2019
accepted:
16
09
2019
pubmed:
24
10
2019
medline:
4
1
2020
entrez:
24
10
2019
Statut:
ppublish
Résumé
Atherogenesis is associated with chronic gut infections; however, the mechanisms are not clear. The aim of the study was to determine whether lipopolysaccharide of E. coli (E. coli LPS) may affect endothelial barrier and modify IL-10 expression in dendritic cells (DCs). Human umbilical vein endothelial cells (HUVECs) and monocyte-derived DCs were treated with E. coli LPS, apolipoprotein B100 (ApoB100) and 7-ketocholesterol (7-kCH) - harmful oxidized form of cholesterol. The effect of E. coli LPS, 7-kCH and ApoB100 on the barrier functions of HUVECs in real-time cell electric impedance sensing system (RTCA-DP) was assessed. Furthermore, the effect of 7-kCH and ApoB100 on barrier functions of HUVECs co-cultured with DCs previously treated with LPS was analyzed. Both E. coli LPS and 7-kCH decreased barrier functions of HUVECs and reduced tight junction protein mRNA expression, whereas ApoB100 increased endothelial barrier. In DCs, ApoB100 and E. coli LPS decreased IL-10 mRNA expression. In HUVECs co-cultured with DCs treated with LPS and subsequently pulsed with ApoB100 or 7-kCH, IL-10 mRNA expression was lower. E. coli LPS-exposed DCs diminished the protective effect of ApoB100 on endothelial integrity and led to the decrease in occludin mRNA expression. LPS potentially derived from gut microflora may destabilize endothelial barrier together with oxidized cholesterol and intensify the immunogenicity of ApoB100.
Substances chimiques
Apolipoprotein B-100
0
IL10 protein, human
0
Ketocholesterols
0
Lipopolysaccharides
0
OCLN protein, human
0
Occludin
0
Tight Junction Proteins
0
Interleukin-10
130068-27-8
7-ketocholesterol
O7676FE78M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-19Subventions
Organisme : National Science Centre
ID : 2011/01/D/NZ5/00925
Informations de copyright
© 2019 APMIS. Published by John Wiley & Sons Ltd.
Références
Chmiela M, Gajewski A, Rudnicka K. Helicobacter pylori vs coronary heart disease - searching for connections. World J Cardiol 2015;7:187.
Kebschull M, Demmer RT, Papapanou PN. "Gum bug, leave my heart alone!"-epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res 2010;89:879.
Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430.
Sessa R, Pietro MD, Filardo S, Turriziani O. Infectious burden and atherosclerosis: a clinical issue. World J Clin Cases 2014;2:240.
Akhi R, Wang C, Nissinen AE, Kankaanpaa J, Bloigu R, Paju S, et al. Salivary IgA to MAA-LDL and oral pathogens are linked to coronary disease. J Dent Res 2019;98:296.
Liljestrand JM, Paju S, Pietiainen M, Buhlin K, Persson GR, Nieminen MS, et al. Immunologic burden links periodontitis to acute coronary syndrome. Atherosclerosis 2018;268:177.
Sun J, Rangan P, Bhat SS, Liu L. A meta-analysis of the association between Helicobacter pylori infection and risk of coronary heart disease from published prospective studies. Helicobacter 2016;21:11.
Clark WF, Sontrop JM, Macnab JJ, Salvadori M, Moist L, Suri R, et al. Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study. BMJ 2010;341:c6020.
Matsushita A, Iwase M, Kato Y, Ichihara S, Ichihara G, Kimata H, et al. Differential cardiovascular effects of endotoxin derived from Escherichia coli or Pseudomonas aeruginosa. Exp Anim 2007;56:339.
Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996;4:430.
Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011;8:110.
d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor. mSystems 2017;2:1-12.
Zhao Y, Cong L, Lukiw WJ. Lipopolysaccharide (LPS) accumulates in neocortical neurons of Alzheimer's disease (AD) brain and impairs transcription in human neuronal-glial primary co-cultures. Front Aging Neurosci 2017;9:407.
Munford RS. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? Infect Immun 2008;76:454.
Bolke E, Jehle PM, Storck M, Nothnagel B, Stanescu A, Orth K. Endotoxin release and endotoxin neutralizing capacity during colonoscopy. Clin Chim Acta 2001;303:49.
Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007;86:1286.
Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008;87:1219.
Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292:G518.
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470.
Chalubinski M, Wojdan K, Gorzelak P, Borowiec M, Broncel M. The effect of oxidized cholesterol on barrier functions and IL-10 mRNA expression in human intestinal epithelium co-cultured with dendritic cells in the transwell system. Food Chem Toxicol 2014;69:289.
Chalubinski M, Zemanek K, Skowron W, Wojdan K, Gorzelak P, Broncel M. The effect of 7-ketocholesterol and 25-hydroxycholesterol on the integrity of the human aortic endothelial and intestinal epithelial barriers. Inflamm Res 2013;62:1015.
Vejux A, Malvitte L, Lizard G. Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Braz J Med Biol Res 2008;41:545.
Chiba H, Osanai M, Murata M, Kojima T, Sawada N. Transmembrane proteins of tight junctions. Biochim Biophys Acta 2008;1778:588.
Blecharz KG, Haghikia A, Stasiolek M, Kruse N, Drenckhahn D, Gold R, et al. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult Scler 2010;16:293.
Jarajapu YP, Cai J, Yan Y, Li Calzi S, Kielczewski JL, Hu P, et al. Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3. PLoS ONE 2012;7:e39398.
Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D, et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 2011;6:e16631.
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204.
Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158.
Nilsson J, Bjorkbacka H, Fredrikson GN. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr Opin Lipidol 2012;23:422.
Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998;18:884.
Hayashi C, Gudino CV, Gibson FC 3rd, Genco CA. Review: Pathogen-induced inflammation at sites distant from oral infection: bacterial persistence and induction of cell-specific innate immune inflammatory pathways. Mol Oral Microbiol 2010;25:305.
Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006;27:2530.
Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011;123:1083.
Hjerpe C, Johansson D, Hermansson A, Hansson GK, Zhou X. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe(−/−) mice. Atherosclerosis 2010;209:436.
Rudnicka K, Miszczyk E, Matusiak A, Walencka M, Moran AP, Rudnicka W, et al. Helicobacter pylori-driven modulation of NK cell expansion, intracellular cytokine expression and cytotoxic activity. Innate Immun 2015;21:127.